The present invention relates to the use of ROS kinase inhibitors for treating abnormal cell growth in mammals. In particular the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ROS. In particular the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ROS by administration of crizotinib.